Pathology: locally advanced NSCLC - (neo)adjuvant (NA); mNSCLC - L1 - PDL1 negative; NSCLC neoadjuvant setting;
| locally advanced NSCLC - (neo)adjuvant (NA) | mNSCLC - L1 - PDL1 negative | NSCLC neoadjuvant setting | ||
| CheckMate 816, 2022 | CheckMate 227 (NC vs C ; PDL1<1%), 2018 | CheckMate 816, 2022 | ||
| nivolumab plus SoC | 3 | T1 | T1 | T1 |
| placebo plus SoC | 0 | T0 | T0 | |
| pemetrexed plus platin | 0 | T0 |